Dosimetric Impact of the Positional Imaging Frequency for Hypofractionated Prostate Radiotherapy – A Voxel-by-Voxel Analysis

Mona Splinter1,2†, Ilias Sachpazidis3,4†, Tilman Bostel1,5,6†, Tobias Fechter3,4, Constantinos Zamboglou3,4, Christian Thieke7, Oliver Jäkel1,2, Peter E. Huber1,5,8, Jürgen Debus1,5,8, Dimos Baltas3,4 and Nils H. Nicolay1,5,3,4*

1 Heidelberg Institute of Radiation Oncology (HIRO), National Center for Radiation Research in Oncology (NCRO), Heidelberg, Germany, 2 Medical Physics in Radiation Oncology, German Cancer Research Center, Heidelberg, Germany, 3 Department of Radiation Oncology, University of Freiburg – Medical Center, Freiburg im Breisgau, Germany, 4 German Cancer Consortium (DKTK), Partner Site Freiburg, German Cancer Research Center, Heidelberg, Germany, 5 Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center, Heidelberg, Germany, 6 Department of Radiation Oncology, University Medical Center Mainz, Mainz, Germany, 7 Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany, 8 Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany

Background: To investigate deviations between planned and applied treatment doses for hypofractionated prostate radiotherapy and to quantify dosimetric accuracy in dependence of the image guidance frequency.

Methods: Daily diagnostic in-room CTs were carried out in 10 patients in treatment position as image guidance for hypofractionated prostate radiotherapy. Fraction doses were mapped to the planning CTs and recalculated, and applied doses were accumulated voxel-wise using deformable registration. Non-daily imaging schedules were simulated by deriving position correction vectors from individual scans and used to rigidly register the following scans until the next repositioning before dose recalculation and accumulation. Planned and applied doses were compared regarding dose-volume indices and TCP and NTCP values in dependence of the imaging and repositioning frequency.

Results: Daily image-guided repositioning was associated with only negligible deviations of analyzed dose-volume parameters and conformity/homogeneity indices for the prostate, bladder and rectum. Average CTV T did not significantly deviate from the plan values, and rectum NTCPs were highly comparable, while bladder NTCPs were reduced. For non-daily image-guided repositioning, there were significant deviations in the high-dose range from the planned values. Similarly, CTV dose conformity and homogeneity were reduced. While TCPs and rectal NTCPs did not significantly deteriorate for non-daily repositioning, bladder NTCPs appeared falsely diminished in dependence of the imaging frequency.
INTRODUCTION
Prostate cancer is the most common malignancy in men with an estimated incidence ranging between 100 and 170 per 100,000 people per year (1). Radiotherapy is a key treatment modality for prostate cancer patients that results in survival rates comparable to prostatectomy while exhibiting lower rates of urinary incontinence or erectile dysfunction (2–4). Modern treatment techniques including image-guided and intensity-modulated radiotherapy (IMRT) have contributed to reducing late therapy-related toxicities to the bladder and rectum and allowed application of higher fractional and overall treatment doses (5, 6). A deeper understanding about the radiobiology of prostate cancers has established treatment concepts utilizing increasing single doses, and several large randomized trials have investigated the clinical relevance of hypofractionated radiotherapy for prostate cancer treatment (7–9). However, the increasing utilization of high-precision radiation techniques for the treatment of prostate cancer has rendered the application more susceptible to dosimetric deviations from the treatment plan due to inter- and intrafractional alterations in the pelvic anatomy, and the application of higher single doses in a reduced number of treatment fractions may increase the potential for therapeutic misses (10, 11). Regular image guidance using orthogonal X-ray or cone-beam CT (CBCT) imaging is set to accommodate for anatomic changes, and due to the weak soft-tissue contrast of pelvic positional imaging, additional means for positional control such as implanted fiducial markers may help to further improve reproducible treatment positioning for prostate cancer patients.

While the anatomic changes during the course of therapy have been widely studied, the consequences of these changes for the applied radiation doses remain incompletely understood (10–12). The majority of previous publications was based on weekly CT scans and rigid co-registration algorithms and demonstrated significant dosimetric variability for normofractionated IMRT and proton radiotherapy (13–15). So far, very few data are available comparing planned and applied doses for prostate radiotherapy based on daily imaging and deformable imaging registration, and no information is available for hypofractionated treatment concepts (16, 17). Additionally, while many guidelines recommend daily positional imaging for hypofractionated prostate radiotherapy, the majority of patients in the randomized trials did not receive image-guided treatment (18, 19).

Here, we analyzed deviations of the applied treatment doses from the treatment plan on a voxel-by-voxel basis using daily planning CT scans in treatment position performed immediately before each treatment fraction. Additionally, the dosimetric impact of different frequencies for positional imaging was quantified. These data will help to define optimal imaging frequencies and to devise adaptive re-planning strategies for hypofractionated prostate radiotherapy.

Conclusion: Using voxel-by-voxel dose accumulation, we showed for the first time that daily image-guided repositioning resulted in only negligible dosimetric deviations for hypofractionated prostate radiotherapy. Regarding dosimetric aberrations for non-daily imaging, daily imaging is required to adequately deliver treatment.

Keywords: prostate cancer, image-guided radiotherapy, hypofractionation, dosimetry, organs-at-risk, tumor control probability

MATERIALS AND METHODS
Patients
Ten consecutive patients were treated with definitive prostate radiotherapy at the German Cancer Research Center and were included in this analysis. All patients presented with low or intermediate-risk prostate cancer limited to stages T1c to T2b, PSA values ranging below 20 ng/ml and Gleason scores not exceeding 7 (20). The analysis was carried out in accordance with the Declaration of Helsinki (Seventh Revision, 2013) and was approved by the Independent Ethics Committee of the Medical Faculty of the University of Heidelberg, Germany (S-380/2017).

Treatment Planning and Delivery
Patient immobilization was carried out using a ProStep™ pelvic and lower extremity support (Elekta, Stockholm, Sweden). No patient received implanted fiducials prior to radiotherapy. The clinical target volume (CTV) covered the prostate gland for low-risk tumors and also the base of the seminal vesicles for intermediate-risk cancers. The planning target volume (PTV) comprised an additional 7 mm as a setup margin. Treatment plans were generated based on the hypofractionated arm of the CHHiP trial to a total dose of 60 Gy in 20 fractions of 3 Gy (7). Dose constraints to the organs-at-risk (OARs) were defined in accordance with the Quantitative Analyses of Normal Tissue Effects in the Clinic (21–23). Treatment plans for a step-and-shoot IMRT using 9 co-planar fields were generated on the RayStation planning system (RaySearch Laboratories, Stockholm, Sweden). All patients were instructed to present to each treatment fraction with a comfortably filled bladder and an empty rectum.

In-Room CT Imaging
For each treatment fraction, patient positioning on the treatment couch was carried out as described above, and the couch was then rotated into a CT scanner (Primatom; Siemens OCS, Malvern, United States) directly adjacent to the linear accelerator. All patients received daily diagnostic CT imaging in treatment position as a means of position verification. The in-room CT
scanner had been approved for treatment planning scans, and all scans were taken to the same specifications used for the individual planning examinations.

Analysis of Variations and Dose Accumulation

All target volumes and OARs were contoured by a board-certified radiation oncologist according to current guidelines both on the planning CT scan and the daily in-room CT scans (24, 25). Daily position verification imaging was rigidly registered to the planning CTs as routinely done for patient repositioning prior to dose re-calculation. Applied fractional doses were calculated based on the daily imaging, and resulting dose distributions were mapped onto the planning CTs. Daily doses were accumulated on a voxel-by-voxel basis using the RayStation’s deformable image registration module, and dose comparison was carried out against the treatment plan (26). The quality and accuracy of the deformable registration was assessed by a board-certified radiation oncologist based on the prostate contours available for each scan.

Different non-daily imaging schedules were simulated by deriving the position correction vectors from the respective CT scans that was then used to rigidly register the following scans until the next simulated positional imaging to the planning CTs. For thrice weekly imaging, vectors were derived from treatment days 1, 3, 5, 6, 8, 10, 11, 13, 15, 16, 18, and 20. For simulation of a twice weekly imaging schedule, repositioning was simulated based on the scans from days 1, 3, 5, 6, 8, 10, 11, 13, 15, 16, 18, and 20. For weekly imaging simulation, repositioning was simulated based on the scans from days 1, 6, 11, and 16. For simulation of a twice weekly imaging schedule, on days 1, 4, 6, 9, 11, 14, 16, and 19. For weekly imaging simulation, repositioning relied on the scans from days 1, 6, 9, 11, 14, 16, and 19. For simulation of a thrice weekly imaging schedule, vectors were derived on days 1, 3, 5, 6, 8, 10, 11, 13, 15, 16, 18, and 20. For the twice weekly schedule, and on days 1, 3, 5, 6, 8, 10, 11, 13, 15, 16, 18, and 20 for the thrice weekly schedule.

Daily doses were accumulated on a voxel-by-voxel basis using the RayStation’s deformable image registration module, and dose comparison was carried out against the treatment plan (26). The quality and accuracy of the deformable registration was assessed by a board-certified radiation oncologist based on the prostate contours available for each scan.

The applied dose accumulations were compared within the region receiving >10% of the maximum dose using a 3D gamma analysis to the clinical tolerance level of 3%/3mm (29).

Statistical Analysis

Differences in the dose volume indices between applied and prescribed doses were compared by the Wilcoxon signed-rank test with corresponding two-sided confidence intervals using an in-house software tool developed in Python1. Differences were considered statistically significant for $p < 0.05$.

1https://www.python.org

RESULTS

Impact of Interfractional Variations on Dose Distribution

Deviations of the applied doses were compared with the treatment plan regarding the CTV, PTV, bladder and rectum (Figure 1). Due to its well-known changes in volume during radiotherapy, the bladder exhibited the highest variability between the applied and prescribed doses, and the dosimetric deviations were most pronounced in the higher-dose range for both the bladder and the rectum (Figure 2 and Supplementary Figure 1). The differences in the dose-volumetric indices between the accumulation of applied fractional doses and the treatment plan are summarized in Table 1. Upon daily rigid repositioning, the doses to the CTV did only demonstrate minor deviations ranging below 1% for all tested dose volume indices. The accumulated $D_{50}$ and $D_{mean}$ for the CTV deviated by only 0.3% from the planned doses ($p = 0.160$ for $D_{50}$; $p = 0.557$ for $D_{mean}$). No significant deviations were observed for the dose conformity indices of the CTV ($p = 0.160$ for CI, $p = 0.084$ for COIN, and a small decrease was only noted for dose homogeneity ($p = 0.002$ for HI, $p = 0.846$ for gEUD). As a result, the TCP and $P +$ values for the CTV were comparable for the planned and applied treatment doses (87.8 vs. 88.1%; $p = 0.695$ for TCP; 81.5 vs. 81.5%; $p = 0.625$ for $P +$) (Figure 3). For the PTV, the differences were more pronounced in the low dose region with the applied $D_{98}$ deviating by 20.5% ($p = 0.002$) compared to the planned $D_{98}$. In the high-dose region, only the applied $V_{55}$ deviated from the plan by 8.9% ($p = 0.002$), while the $D_{3}$ and $D_{2}$ values were comparable ($p = 0.131$ for $D_{5}$; $p = 0.064$ for $D_{2}$).

Considering the known alterations in bladder volumes during radiotherapy, the applied $D_{mean}$ and $D_{50}$ varied by 8.2 and 39.8% from the planned doses, respectively ($p = 0.432$ for $D_{mean}$; $p = 0.131$ for $D_{50}$); however, no statistically significant difference could be obtained for any tested dose-volume parameter. For the rectum, the accumulated average $D_{mean}$ and $D_{50}$ values deviated by only 2.2 and 5.0%, respectively ($p = 0.846$ for $D_{mean}$; $p = 0.625$ for $D_{50}$), and all tested dose-volume indices did only show non-significant variations from the treatment plan (Table 1). Similarly, the NTCP values derived from the accumulated or planned doses were comparable and did not significantly deviate for either the bladder ($p = 0.322$) or the rectum ($p = 0.770$) (Figure 4).

Impact of Positional Imaging Frequency on Dose Distribution

To quantify the dosimetric consequences of various non-daily position verification CT schedules in comparison to daily positional imaging, CT-based correction vectors were derived on days 1, 3, 5, 6, 8, 10, 11, 13, 15, 16, 18, and 20 for the thrice weekly schedule, on days 1, 4, 6, 9, 11, 14, 16, and 19 for the twice weekly schedule, and on days 1, 6, 11, and 16 for the weekly schedule, and were used to register all consecutive scans up to the next positional imaging onto the planning scan. Resulting applied doses were accumulated and compared to the dose accumulation resulting from daily CT-based repositioning.
Splinter et al. Interfractional Variation of Hypofractionated Prostate Radiotherapy

For the CTV, no significant dosimetric deviations of the applied from the planned doses were observed, when positional imaging was simulated thrice weekly. For the twice weekly and weekly schedules, the V55 and D1cc deviated significantly from the treatment plan, while TCP and P + values were comparable (Table 1 and Figure 3). In contrast, for all non-daily imaging schedules, applied doses to the PTV deviated considerably from the planned doses: Alterations were most pronounced in the high-dose region with significant deviations of the D5 (p = 0.027 for thrice weekly, p = 0.014 for twice weekly, p = 0.010 for weekly imaging), the D2 (p = 0.006 for thrice weekly, p = 0.004 for twice weekly, p = 0.002 for weekly imaging), the D1cc (p = 0.020 for thrice weekly, p = 0.014 for twice weekly, p = 0.010 for weekly imaging) and the V55 (p = 0.002 for all non-daily imaging schedules).

For the bladder, small but significant differences between the applied and prescribed doses were only noted for the D5 in all non-daily imaging schedules (p = 0.006 for thrice weekly and twice weekly, p = 0.004 for weekly imaging), and the dose uniformity was reduced for thrice weekly (p = 0.049) and weekly CT-based positional correction (p = 0.027). All other dose volume parameters for the accumulated doses did not significantly deviate from the plan, likely due to a large inter-individual variability regarding bladder volumes (Table 1). The NTCP for the bladder was found significantly lower for all non-daily repositioning concepts in comparison to daily positional correction (p = 0.010 for thrice weekly, p = 0.014 for twice weekly, p = 0.004 for weekly imaging) (Figure 4). For the rectum, deviations of the accumulated fractional doses from the planned doses did not reach statistical significance for any tested dose volume parameter, and the NTCP values did not significantly deviate for any non-daily imaging algorithm.

The gamma passing rates to a clinical tolerance level of 3%/3mm were reduced by an average of 1.5% for thrice weekly
FIGURE 2 | Summed dose-volume histograms for the prostate CTV (blue lines), PTV (orange lines), bladder (green lines) and rectum (red lines) for treatment plans and dose accumulations in dependency of the image-guided repositioning frequency. Lighter-colored bands represent the 95% confidence intervals for each curve.

imaging ($p = 0.002$), 4.9% for twice weekly imaging ($p = 0.006$) and 7.1% for weekly imaging ($p = 0.010$) (Figure 5).

**DISCUSSION**

Dosimetric deviations in prostate radiotherapy resulting from intra- and interfractional anatomic variability have been incompletely understood, and an in-depth comprehension about the dosimetric impact of position verification imaging becomes more important as individual fraction dose are increasing for hypofractionated or even stereotactic treatment approaches (18, 19, 30). Previous analyses have generally been limited by the insufficient quality or frequency of position verification imaging and the lacking availability of elastic image registration tools.

This dataset provides for the first time a comprehensive and voxel-based analysis of the dose deviations resulting from different imaging and repositioning frequencies for hypofractionated prostate radiotherapy. As daily planning quality CT scans and a state-of-the-art elastic image registration tool were used in this analysis, applied doses to the target volumes and organs-at-risk could be precisely accumulated for each treatment fraction and each patient. Our data revealed that daily CT-based position correction did not lead to significant dosimetric deviations of the applied from the prescribed treatment doses irrespective of the daily pelvic anatomy. However, repositioning based on non-daily positional imaging resulted in significant dose differences especially in the high-dose range and diminished dose conformity and homogeneity to the target volume in case of hypofractionation.

Previous analyses have employed varying strategies to accumulate fractional doses for prostate cancer radiotherapy on the basis of widely available but low-quality CBCT imaging, including enhanced or iterative CBCT approaches, portal dose measurements or rigid registration strategies, albeit with limitations regarding dose mapping (12, 15, 31, 32). Dosimetric
analyses based on daily diagnostic CT imaging have only been reported for proton radiotherapy, as in-room CT scanners are more widely available at the respective facilities, given the necessity for high-resolution imaging to compensate for higher proton range uncertainties due to anatomic alterations (33, 34).

The available evidence concerning the ideal frequency for positional imaging remains somewhat inconclusive. A previous publication reported improvements in target volume coverage and a reduction in high doses to the rectum for daily CBCT imaging and repositioning based on registration (35). It has been suggested that the imaging frequency should direct the choice of PTV margins, although the relevance of the observed dosimetric improvements for the treated patients remains unclear (36, 37). So far, several randomized trials have addressed the clinical relevance of daily CBCT regarding treatment-related toxicities and patient outcomes: A French trial enrolled 470 patients and reported improved progression-free survival and reduced late rectal toxicity for the cohort receiving daily CBCT. However,

| TABLE 1 | Average and standard deviation of differences between applied and planned dose-volume indices for daily and different non-daily CT-based repositioning concepts. Negative values represent decreases in accumulated doses. |
|---------|---------------------------------------------------------------|
|         | Daily P value | Thrice weekly P value | Twice weekly P value | Weekly P value |
| CTV     |               |                     |                      |               |
| D98 (Gy)| −0.008        | 0.770               | −0.011               | 0.557         |
| D50 (Gy)| −0.003        | 0.160               | −0.003               | 0.232         |
| Dmean (Gy)| −0.003   | 0.557               | −0.003               | 0.846         |
| D5 (Gy) | 0.003         | 0.492               | 0.004                | 0.322         |
| D2 (Gy) | 0.005         | 0.322               | 0.008                | 0.131         |
| D1cc (Gy)| 0.004      | 0.375               | 0.009                | 0.557         |
| V55 (%) | 0.000         | 0.281               | 0.001                | 0.142         |
| gEUD (Gy)| −0.007     | 0.846               | −0.004               | 1.000         |
| CI      | −0.271        | 0.160               | −0.259               | 0.160         |
| COIN    | −0.358        | 0.084               | −0.600               | 0.037*        |
| HI      | 0.016         | 0.002*              | 0.019                | 0.002*        |
| PTV     |               |                     |                      |               |
| D98 (Gy)| 0.205         | 0.002*              | 0.198                | 0.002*        |
| D50 (Gy)| 0.000         | 0.770               | 0.002                | 0.492         |
| Dmean (Gy)| 0.019     | 0.100*              | 0.022                | 0.010*        |
| D5 (Gy) | 0.005         | 1.311               | 0.009                | 0.027*        |
| D2 (Gy) | 0.008         | 0.064               | 0.012                | 0.006*        |
| D1cc (Gy)| 0.325       | 0.010*              | 0.312                | 0.020*        |
| V55 (%) | 0.089         | 0.002*              | 0.105                | 0.002*        |
| gEUD (Gy)| 0.268       | 0.020*              | 0.264                | 0.014*        |
| CI      | −0.003        | 0.846               | 0.084                | 0.275         |
| COIN    | −0.003        | 0.695               | 0.082                | 0.232         |
| HI      | 0.020         | 0.002*              | 0.029                | 0.002*        |
| Bladder |               |                     |                      |               |
| D50 (Gy)| −0.398        | 0.131               | −0.359               | 0.160         |
| Dmean (Gy)| −0.082    | 0.432               | −0.006               | 0.696         |
| D25 (Gy)| −0.072        | 0.375               | 0.022                | 0.696         |
| D5 (Gy) | 0.005         | 0.100               | 0.022                | 0.006*        |
| D1cc (Gy)| 0.002       | 0.193               | 0.004                | 0.275         |
| V55 (%) | −0.103        | 0.846               | 0.158                | 0.131         |
| V45 (%) | −0.120        | 0.695               | 0.004                | 0.625         |
| gEUD (Gy)| −0.020      | 0.770               | 0.024                | 0.049**       |
| Rectum  |               |                     |                      |               |
| D50 (Gy)| 0.050         | 0.625               | 0.022                | 0.275         |
| Dmean (Gy)| 0.022     | 0.846               | 0.022                | 0.770         |
| D60 (Gy)| 0.058         | 0.922               | 0.030                | 0.625         |
| D30 (Gy)| 0.097         | 0.770               | 0.015                | 1.000         |
| D15 (Gy)| 0.013         | 0.492               | 0.007                | 0.696         |
| D5 (Gy) | 0.006         | 0.322               | 0.006                | 0.375         |
| D1cc (Gy)| −0.022     | 0.695               | −0.062               | 0.375         |
| V55 (%) | 0.040         | 0.846               | 0.032                | 0.922         |
| V45 (%) | 0.145         | 0.557               | 0.063                | 0.770         |
| gEUD (Gy)| 0.015       | 0.492               | −0.001               | 0.625         |

CTV, clinical target volume; gEUD, generalized equivalent uniform dose; CI, conformity index; COIN, conformal index; HI, homogeneity index. *p < 0.05. The asterisk and the bold print mark the significant values in table.
a Scandinavian trial failed to demonstrate any benefit of daily CBCT and PTV margin reduction regarding treatment-related toxicities or quality-of-life parameters in comparison to weekly portal imaging (38). For hypofractionated radiotherapy, it is conceivable that due to the increases in single doses, anatomy-related dosimetric deviations for individual treatment fractions may have a higher impact and may therefore warrant more frequent imaging as compared to normofractionation concepts. A substudy within the CHHiP trial analyzed the relevance of image guidance and PTV margin reduction for hypofractionated prostate radiotherapy and reported a borderline improvement of grade ≥2 late rectal toxicities only for image guidance and margin reduction, while standard-margin image-guided and non-image-guided therapies produced highly comparable results; bladder toxicities or patient outcomes appeared comparable in all three subgroups (18). The vast majority of patients in the CHHiP trial received 2D image guidance based on implanted fiducial markers, and the utilization of these markers may impact deviations of the applied doses from the treatment plan. However, fiducial markers seem to only result in insignificant dosimetric benefits in comparison to markerless registration strategies if daily CT imaging is available (12). The advent of hybrid MR-linear accelerators may further reduce anatomic and dosimetric deviations during the course of hypofractionated prostate radiotherapy, e.g., by utilizing the superior soft tissue contrast and the possibility for real-time prostate tracking: MR-guided imaging concepts would thereby allow to compensate for both interfractional and intrafractional motion (39, 40). In contrast to focusing on the dosimetric consequences of underlying anatomic pelvic alterations, novel position correction...
strategies have been proposed that guide repositioning based on the accumulated doses during treatment (41). The availability of voxel-wise information regarding accumulated doses in our dataset may help to further devise dose-directed repositioning strategies to compensate for already accumulated deviations during the course of radiotherapy.
Although our analysis is based on daily diagnostic-quality CT imaging and state-of-the-art elastic image registration and is therefore able to provide comprehensive voxel-wise dosimetric data, it has limitations: Beyond interfractional variability and setup errors, applied doses may also be influenced by intrafractional motion of the prostate that could not be quantified in our dataset. As our chosen methodology did not allow for intrafractional imaging, the impact of intrafractional variability for hypofractionated prostate radiotherapy needs to be addressed separately. All patients analyzed here received pre-treatment coaching about rectal and bladder filling as well as feedback in case of notable deviations of their pelvic anatomy from that of the planning CT. This coaching and a resulting consistency in rectal and bladder filling may have contributed to the relatively moderate dosimetric deviations observed in the simulated non-daily imaging schedules, and patients without coaching may in fact demonstrate significantly higher dosimetric deviations for non-daily imaging-guided repositioning. Additionally, generous PTV margins of 7 mm may at least have partly compensated for the deficiencies of all non-daily imaging schedules and hence to the reasonable TCP values observed. While the seminal CHHiP hypofractionation trial used PTV margins up to 10 mm, several newer clinical trials with daily positional imaging have employed smaller PTV margins ranging at around 5 mm (42, 43); the voxel-wise dosimetric data obtained from our analysis may help to devise concepts for PTV margin reduction that may in turn reduce treatment-related toxicities for hypofractionated prostate radiotherapy.

The transferability of our data to high-risk or locally advanced prostate cancers as well as other concepts of hypofractionation warrant further analyses, as differing treatment margins or treatment times may also influence dose-volume parameters. Nevertheless, we provide for the first time a comprehensive and voxel-by-voxel analysis of the dosimetric effects of interfractional variations for hypofractionated prostate radiotherapy and the resulting consequences for the frequency of position verification imaging. These data will also help to devise strategies for adaptive planning of hypofractionated radiation treatments.

**CONCLUSION**

Using voxel-by-voxel dose accumulation, we showed for the first time that daily image-guided repositioning resulted in only negligible dosimetric deviations for hypofractionated prostate radiotherapy. Regarding the observed dosimetric aberrations for the simulated non-daily imaging algorithms, daily imaging seems to be required to adequately deliver treatment. These data will help to develop adaptive re-planning strategies for hypofractionated prostate radiotherapy.

**DATA AVAILABILITY STATEMENT**

The datasets presented in this article are not readily available because German federal laws protect patient data and prohibit these data from being transferred or shared. Requests to access the datasets should be directed to nils.nicolay@uniklinik-freiburg.de.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by Independent Ethics Committee of the University of Heidelberg. The patients/participants provided their written informed consent to participate in this study.

**AUTHOR CONTRIBUTIONS**

TB, PH, JD, and NN planned and carried out treatment. MS, IS, TB, TF, OJ, DB, and NN analyzed the data. NN wrote the manuscript. IS, CZ, CT, PH, and DB helped with writing the manuscript. JD helped with data discussion. All authors contributed to the article and approved the submitted version.

**ACKNOWLEDGMENTS**

We acknowledge the work of Annette Miltner, Peter Haering, and Clemens Lang who helped with image processing and contouring of the organs-at-risk.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2020.564068/full#supplementary-material

**Supplementary Figure 1** | Summed dose-volume histograms of the gEUD2Gy for the prostate CTV (blue lines), PTV (orange lines), bladder (green lines) and rectum (red lines) for treatment plans and dose accumulations in dependency of the image-guided repositioning frequency. Lighter-colored bands represent the 96% confidence intervals for each curve.

**REFERENCES**

1. Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends-an update. *Cancer Epidemiol Biomarkers Prev.* (2016) 25:16–27. doi: 10.1158/1055-9965.EPI-15-0578
2. Hamdy FC, Donovan JL, Lane JA, Mason M, Meta Case C, Holding P, et al. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. *N Engl J Med.* (2016) 375:1415–24. doi: 10.1056/NEJMoa1606220
3. Kupelian PA, Potters I, Khuntia D, Ciezia JR, Reddy CA, Reuther AM, et al. Radical prostatectomy, external beam radiotherapy or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. *Int J Radiat Oncol Biol Phys.* (2004) 58:25–33. doi: 10.1016/S0360-3016(03)00784-3
11. Bylund KC, Bayouth JE, Smith MC, Hass AC, Bhatia SK, Buatti JM. Analysis of interfractional variation of hypofractionated prostate radiotherapy: a randomized clinical trial. Cancer. (2016) 122:2004–11. doi: 10.1002/cncr.29983

12. Bruner DW, Hunt D, Michalski JM, Bosch WR, Galvin JM, Amin M, et al. Preliminary patient-reported outcomes analysis of 3-dimensional radiation therapy versus intensity-modulated radiation therapy on the high-dose arm of the radiation therapy oncology group (RTOG) 0126 prostate cancer trial. Cancer. (2015) 121:2422–30. doi: 10.1002/cncr.29362

13. Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHEHIP trial. Lancet Oncol. (2016) 17:1047–60. doi: 10.1016/S1470-2045(16)30102-4

14. de Vries KC, Wortel RC, Hoop EO, Heemsbergen WD, Pos FJ, Incrocci PL. Hypofractionated versus conventionally fractionated radiotherapy for patients with intermediate- or high-risk, localized prostate cancer: 7-year outcomes from the randomized, multi-centre, open-label, phase 3 HYPRO trial. Int J Radiat Oncol Biol Phys. (2019) 106:108–15. doi: 10.1016/j.ijrob.2019.09.007

15. Moteabbed M, Trofimov A, Sharp GC, Wang Y, Zietman AL, Efstathiou JA, et al. Study of robustness of IMPT and Proton Therapy-implications for imaging frequency and treatment adaptation. Radiother Oncol. (2017) 193:38–45. doi: 10.1016/j.ijrobp.2016.06.017

16. Mirabalbell R, Roberts SA, Zubizarreta E, Hendry JH. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: alpha/beta = 1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys. (2012) 82:e17–24. doi: 10.1016/j.ijrob.2010.10.075

17. Verma V, Chen S, Zhou S, Enke CA, Wah AO. Prostate bed target interfractional motion using RTOG consensus definitions and daily CT on rails: does target motion differ between superior and inferior portions of the clinical target volume? Strahlenther Onkol. (2017) 193:38–45. doi: 10.1007/s00066-017-1077-6

18. Bylund KC, Bayouth JE, Smith MC, Hass AC, Bhatia SK, Buatti JM. Analysis of interfractional prostate motion using megavoltage cone beam computed tomography. Int J Radiat Oncol Biol Phys. (2008) 72:949–56. doi: 10.1016/j.ijrobp.2008.07.002

19. Wust P, Joswig M, Graf R, Böhmer D, Beck M, Barelkowski T, et al. Dosimetric implications of inter- and intrafractional prostate positioning errors during tomotherapy: comparison of gold marker-based registrations with native MVCT. Strahlenther Onkol. (2017) 193:700–6. doi: 10.1007/s00066-017-1141-x

20. Zheng X, Dong L, Lee AK, Cox JD, Kuban DA, Zhu RX, et al. Effect of anatomic motion on proton therapy dose distributions in prostate cancer treatment. Int J Radiat Oncol Biol Phys. (2007) 67:620–9. doi: 10.1016/j.ijrobp.2006.10.008

21. Stokkel PM, Boersma MI, van der Heijden GJ, Kok K, Verbakel RM, et al. A conformal index (COIN) to evaluate implant quality and dose specification in brachytherapy. Int J Radiat Oncol Biol Phys. (1998) 40:515–24. doi: 10.1016/S0360-3016(97)00732-3

22. Clasie BM, Sharp GC, Seco J, Flanz JB, Kooy HM. Numerical solutions of the gamma-index in two and three dimensions. Phys Med Biol. (2012) 57:6981–97. doi: 10.1088/0031-9155/57/21/6981

23. Bostel T, Pfaffenberger A, Delorme S, Dreher C, Eichner G, Haering P, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. (2010) 76(3 Suppl):S116–22. doi: 10.1016/j.ijrobp.2009.09.020

24. Wortel RC, Hoop EO, Heemsbergen WD, Pos FJ, Incrocci PL. Hypofractionated versus conventionally fractionated radiotherapy for patients with intermediate- or high-risk, localized prostate cancer: 7-year outcomes from the randomized, multi-centre, open-label, phase 3 HYPRO trial. Int J Radiat Oncol Biol Phys. (2019) 106:108–15. doi: 10.1016/j.ijrob.2019.09.007

25. Splinter M, Bostel T, Sachapzidis I, Splinter M, Bougaf N, Fechter T, Zamboglou C, et al. Dosimetric impact of interfractional variations in prostate cancer radiotherapy-implications for imaging frequency and treatment adaptation. Front Oncol. (2019) 9:940. doi: 10.3389/fonc.2019.00940

26. Moteabbed M, Trofimov A, Sharp GC, Wang Y, Zietman AL, Efstathiou JA, et al. Prospective feasibility analysis of a novel off-line approach for MR-guided radiotherapy. Strahlenther Onkol. (2018) 194:425–34. doi: 10.1007/s00066-017-1258-y

27. van Zijtveld M, Dirkx M, Breurers M, Kuipers R, Heijmen B. Evaluation of the ‘dose of the day’ for IMRT prostate cancer patients derived from portal dose measurements and cone-beam CT. Radiother Oncol. (2010) 96:172–7. doi: 10.1016/j.radonc.2010.05.015

28. Owen R, Kron T, Foroudi F, Milner A, Cox J, Duchesne G. Interfraction prostate rotation determined from in-room computerized tomography images. Med Dosim. (2011) 36:188–94. doi: 10.1089/medi.2010.10302

29. Maeda Y, Sato Y, Minami H, Yasukawa Y, Yamamoto K, Tamamura H, et al. Positioning accuracy and daily dose assessment for prostate cancer treatment using in-room CT image guidance at a proton therapy facility. Med Phys. (2018) 45:1832–43. doi: 10.1002/mp.12858

30. Wust P, Joswig M, Graf R, Böhmer D, Beck M, Barelkowski T, et al. Dosimetric implications of inter- and intrafractional prostate positioning errors during tomotherapy: comparison of gold marker-based registrations with native MVCT. Strahlenther Onkol. (2017) 193:700–6. doi: 10.1007/s00066-017-1141-x

31. Zheng X, Dong L, Lee AK, Cox JD, Kuban DA, Zhu RX, et al. Effect of anatomic motion on proton therapy dose distributions in prostate cancer treatment. Int J Radiat Oncol Biol Phys. (2007) 67:620–9. doi: 10.1016/j.ijrobp.2006.10.008

32. Splinter M, Bostel T, Sachapzidis I, Splinter M, Bougaf N, Fechter T, Zamboglou C, et al. Dosimetric impact of interfractional variations in prostate cancer radiotherapy-implications for imaging frequency and treatment adaptation. Front Oncol. (2019) 9:940. doi: 10.3389/fonc.2019.00940

33. Splinter M, Bostel T, Sachapzidis I, Fechter T, Zamboglou C, Jakel O, et al. Dosimetric impact of interfractional variations for post-prostatectomy radiotherapy to the prostatic fossa-relevance for the frequency of position verification imaging and treatment adaptation. Front Oncol. (2019) 9:1191. doi: 10.3389/fonc.2019.01191

34. Murray J, Griffin C, Guildford S, Syndikus I, Staffurth J, Panades M, et al. A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer. Radiother Oncol. (2019) 142:62–71. doi: 10.1016/j.radonc.2019.10.017

35. Bostel T, Pfaffenberger A, Delorme S, Dreher C, Eichner G, Haering P, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. (2010) 76(3 Suppl):S116–22. doi: 10.1016/j.ijrobp.2009.09.020

36. Li W, Vassil A, Godley A, Mossolly LM, Shang Q, Xia P. Using daily diagnostic quality images to validate planning margins for prostate interfractional variations. J Appl Clin Med Phys. (2016) 17:61–74. doi: 10.1120/jacmp.v17i3.5923

37. Shelley LEA, Scaife JE, Romanchikova M, Harrison K, Forman JR, Bates AM, et al. Delivered dose can be a better predictor of rectal toxicity than...
planned dose in prostate radiotherapy. *Radiother Oncol.* (2017) 123:466–71. doi: 10.1016/j.radonc.2017.04.008

38. Tondel H, Lund JA, Lydersen S, Wanderas AD, Aksnessaether B, Jensen CA, et al. Radiotherapy for prostate cancer—does daily image guidance with tighter margins improve patient reported outcomes compared to weekly orthogonal verified irradiation? Results from a randomized controlled trial. *Radiother Oncol.* (2018) 126:229–35. doi: 10.1016/j.radonc.2017.10.029

39. Tyagi N, Fontenla S, Zelefsky M, Chong-Ton M, O stimulate K, Shah N, et al. Clinical workflow for MR-only simulation and planning in prostate. *Radiother Oncol.* (2017) 121:119. doi: 10.1016/s13014-017-0854-4

40. de Muinck Keizer DM, Pathmanathan AU, Andreychenko A, Kerkmeijer LGW, van der Voort van Zyp JRN, Tree AC, et al. Fiducial marker based intrafraction motion assessment on cine-MR for MR-Linac treatment of prostate cancer. *Phys Med Biol.* (2019) 64:07NT02. doi: 10.1088/1361-6560/ab09a6

41. Kurz C, Suss P, Arrasmeyer C, Haehnle J, Teichert K, Landry G, et al. Dose-guided patient positioning in proton radiotherapy using multicriteria-optimization. *Z Med Phys.* (2018) 29:216–28. doi: 10.1016/j.zemedi.2018.10.003

42. Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, et al. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. *Lancet Oncol.* (2019) 20:1531–43. doi: 10.1016/S1470-2045(19)30569-8

43. South CP, Khoo VS, Naismith O, Norman A, Dearnaley DP. A comparison of treatment planning techniques used in two randomised UK external beam radiotherapy trials for localised prostate cancer. *Clin Oncol (R Coll Radiol).* (2008) 20:15–21. doi: 10.1016/j.clon.2007.10.012

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Splinter, Sachpazidis, Bostel, Fechter, Zamboglou, Thieke, Jakel, Huber, Debus, Baltas and Nicolay. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.